Biotech Startups

Ribomic is a company with a U.S. subsidiary engaged in research and development, including pharmaceutical and research-ethics-related activities. The page describes its compliance program, ethics committee, employee training, whistleblower hotline, and management of public research funding.

2 investors

Reborna Biosciences is a Japanese biotech company that researches and develops RNA-targeting small-molecule drugs for hereditary rare diseases. Founded in 2018, it operates from the Shonan iPark research campus.

2 investors

Kyoto Drug develops novel therapeutic drugs for rare and difficult-to-treat ocular diseases including retinal artery occlusion and retinitis pigmentosa, using a new small-molecule compound (KUS agent) based on research from Kyoto University.

2 investors

C&R Research is a contract research organization providing end-to-end clinical trial services, including regulatory and non-regulatory trials as well as multinational studies. It has conducted around 1,800 clinical trials, including 79 global multinational trials, over 29 years.

1 investor

Inner Resource develops and operates web content platforms and systems, offering services in content planning, production, management, and advertising-related operations.

1 investor

TL Genomics develops in vitro diagnostic medical products and healthcare testing services, focusing on bone marrow transplant testing, chromosome analysis for disease risk and fertility assessment, and related medical services.

1 investor

Cellusion is a regenerative medicine company developing innovative technologies and products based on patient-centric research across disease areas where regenerative medicine can create new therapeutic value.

1 investor

Robo is an AI platform that automates research and evaluation of external biopharma assets, using AI agents to search across 100M+ primary data sources such as publications, trial registries, patents, and conference abstracts and score them against custom criteria. It serves business development and research teams in the biopharma industry.

1 investor

1517 is an early-stage venture capital fund and community that backs college dropouts, uncredentialed founders, and deep-tech scientists from the idea/R&D phase through the seed stage. Founded by cofounders of the Thiel Fellowship, it invests across software, hardware, and deep tech, and also runs a grant program and a global community of hackers, makers, and scientists.

1 investor

1928 Diagnostics provides a cloud-based bioinformatics platform that transforms complex genomic sequencing data into actionable insights for researchers, healthcare providers, and organizations. The platform automates genomic analysis workflows, making advanced analytics accessible without requiring specialized computational expertise or on-site infrastructure.

1 investor

20/20 BioLabs develops laboratory blood tests using machine learning for the early detection of cancers and chronic diseases, including a multi-cancer early detection (MCED) protein tumor marker test and an inflammation biomarker test. Its tests use at-home upper-arm capillary blood collection and target individuals and healthcare providers.

1 investor

20n uses machine learning and computational biology to predict DNA sequences for industrial biotech and pharmaceutical applications. The company serves manufacturing firms developing biologically-based alternatives to traditional chemical production of fuels, materials, therapeutics, and specialty chemicals.

1 investor

2AB BioscienceS develops first-in-class small molecule therapeutics targeting the 5-HT2A receptor for ophthalmology and central nervous system disorders. The platform uses structure-guided design to create therapies aimed at tissue regeneration, inflammation resolution, and neural circuit restoration.

1 investor

2bull MeDiTherapy develops in-vitro diagnostic medical devices, including TAP, a blood test designed to detect thoracic and abdominal aortic aneurysms. The company focuses on early detection and monitoring diagnostics for cardiovascular disease.

1 investor

2cureX develops IndiTreat®, a 3D functional precision medicine test that grows patient-derived cancer cells as 3D microtumors (tumoroids) from a tumor biopsy to profile drug sensitivity and guide individualized therapy selection. The company serves oncologists and healthcare professionals, providing drug-response reports to inform cancer treatment decisions, and brings its diagnostic products through EU regulatory and reimbursement pathways.

1 investor

A biotech company focused on microbiome and metabolomics research for gastrointestinal health applications, with leadership and scientific advisory rooted in academic medicine and regulatory expertise.

1 investor

3Brain develops microchip-based technology for recording and analyzing cell activity in life science research, combining microelectronics with biology to enable precise real-time monitoring of electrogenic cells. The company serves researchers in academia and industry, operating in the bioelectronics and life sciences sector.

1 investor

3C Therapeutics develops therapeutics using targeted protein degradation, centered on a proprietary modular Degrader-Antibody Conjugate (DAC) platform (TriCore) that delivers intracellular protein degraders via monoclonal antibodies. The company focuses on drug discovery for previously inaccessible targets through a ligand-independent conjugation approach.

1 investor

3D OrthoBiologic Solutions develops and commercializes 3D-printed bone graft scaffolds for surgery and 3D cell culture technologies, targeting the treatment of bone defects and diseases. Its work focuses on orthopedic and oral/maxillofacial reconstructive and regenerative medicine.

1 investor

3F is a Canadian circular economy company that diverts waste and converts it into products and ingredients, including offerings for the pet food industry. It focuses on sustainability and job creation in Newfoundland and Labrador.

1 investor

3Helix develops and sells collagen hybridizing peptides (CHP) and related conjugates for research and diagnostic applications. The company's products are designed to detect and bind denatured collagen chains in both laboratory and in vivo settings.

1 investor

3PBIOVIAN is a global Contract Development and Manufacturing Organization (CDMO) providing end-to-end biopharmaceutical manufacturing services for biotech and pharma companies. The company offers microbial and mammalian protein expression, viral vector production, cell therapy, plasmid DNA production, and fill & finish services across multiple locations in Spain, Finland, and the United States.

1 investor

3X4 Genetics provides direct-to-consumer genetic testing and personalized health recommendations based on DNA analysis, focusing on nutrient needs, disease prevention, weight management, and stress response. The company delivers actionable insights through a mobile app and optional practitioner consultations in the digital health and wellness sectors.

1 investor

Laza Medical develops AI-powered robotic systems and imaging solutions for structural heart and electrophysiology procedures. The company serves interventional cardiologists and healthcare systems seeking to optimize clinical workflows.

1 investor